With 0.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.79 million shares. The 52-week range on HCAT shows that it touched its highest point at $9.24 and its lowest point at $3.76 during that stretch. It currently has a 1-year price target of $8.50. Beta for the stock currently stands at 1.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HCAT was down-trending over the past week, with a drop of -8.14%, but this was down by -27.16% over a month. Three-month performance dropped to -45.97% while six-month performance fell -43.10%. The stock lost -50.40% in the past year, while it has lost -39.32% so far this year. A look at the trailing 12-month EPS for HCAT yields -1.15 with Next year EPS estimates of 0.43. For the next quarter, that number is -0.00. This implies an EPS growth rate of 5.25% for this year and 45.23% for next year. EPS is expected to grow by 39.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 38.24%.
Float and Shares Shorts:
At present, 70.21 million HCAT shares are outstanding with a float of 66.41 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HCAT since 11 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.36909 being high and $0.25553 being low. For HCAT, this leads to a yearly average estimate of $0.31231. Based on analyst estimates, the high estimate for the next quarter is $0.12 and the low estimate is $0.03. The average estimate for the next quarter is thus $0.07.
